Biblio

Filters: Author is Wingard, John R [Clear All Filters]

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

A

Shaw BE, Logan BR, Kiefer DM, Chitphakdithai P, Pedersen TL, Abdel-Azim H, Abidi MH, Akpek G, Diaz MA, Artz AS, et al. An Analysis of the Effect of Race, Socioeconomic Status and Center Size on Unrelated NMDP Donor Outcomes: Donor Toxicities are More Common at Low Volume Bone Marrow Collection Centers. Biol Blood Marrow Transplant. 2015.

C

Arora M, Hemmer MT, Ahn KWoo, Klein JP, Cutler CS, Urbano-Ispizua A, Couriel DR, Alousi AM, Gale RPeter, Inamoto Y, et al. CIBMTR Chronic GVHD Risk Score Predicts Mortality in an Independent Validation Cohort. Biol Blood Marrow Transplant. 2014.

Lutfi F, Iv WPaul Skelt, Wang Y, Rosenau E, Farhadfar N, Murthy H, Cogle CR, Brown R, Hiemenz J, Wingard JR, et al. Clinical predictors of delayed engraftment in autologous hematopoietic cell transplant recipients. Hematol Oncol Stem Cell Ther. 2019.

Hsu JW, Shaw BE, Kim S, Logan BR, Sees JA, Confer DL, Pulsipher MA, Shah N, Switzer GE, Abidi MH, et al. Collection of Peripheral Blood Progenitor Cells in One Day is Associated with Decreased Donor Toxicity compared to Two Days in Unrelated Donors. Biol Blood Marrow Transplant. 2020.

Mauskopf J, Chirila C, Graham J, Gersten ID, Leather H, Maziarz RT, Baden LR, Bolaños-Meade J, M Y Brown J, Walsh TJ, et al. Comparative cost-effectiveness analysis of voriconazole and fluconazole for prevention of invasive fungal infection in patients receiving allogeneic hematopoietic cell transplants. Am J Health Syst Pharm. 2013;70(17):1518-1527.

Khera N, Majhail NS, Brazauskas R, Wang Z, He N, Aljurf MD, Akpek G, Atsuta Y, Beattie S, Bredeson CN, et al. Comparison of Characteristics and Outcomes of Trial Participants and Non-participants: Example of Blood and Marrow Transplant Clinical Trials Network (BMT-CTN) 0201 Trial. Biol Blood Marrow Transplant. 2015.

D

Norkin M, Wingard JR. Diagnostic strategies for invasive fungal infections in patients with hematologic malignancies and hematopoietic stem cell transplant recipients. J Natl Compr Canc Netw. 2013;11(8):941-9.

Farhadfar N, Kelly DL, Mead L, Nair S, Colee J, Irizarry VG, Murthy HS, Brown RA, Hiemenz JW, Hsu JW, et al. Dietary intake and Diet Quality of Hematopoietic Stem Cell Transplant Survivors. Biol Blood Marrow Transplant. 2020.

E

Katragadda L, McCullough LM, Dai Y, Hsu J, Byrne M, Hiemenz J, May S, Cogle CR, Norkin M, Brown RA, et al. Effect of Melphalan 140 mg/m(2) versus 200 mg/m(2) on Toxicities and Outcomes in Multiple Myeloma Patients Undergoing Single Autologous Stem Cell Transplantation - A single center experience. Clin Transplant. 2016.

I

Brasier AR, Zhao Y, Spratt HM, Wiktorowicz JE, Ju H, L Wheat J, Baden L, Stafford S, Wu Z, Issa N, et al. Improved Detection of Invasive Pulmonary Aspergillosis Arising during Leukemia Treatment Using a Panel of Host Response Proteins and Fungal Antigens. PLoS One. 2015;10(11):e0143165.

Young J-AH, Logan BR, Wu J, Wingard JR, Weisdorf DJ, Mudrick C, Knust K, Horowitz MM, Confer DL, Dubberke ER, et al. Infections following Transplantation of Bone Marrow or Peripheral-Blood Stem Cells from Unrelated Donors. Biol Blood Marrow Transplant. 2015.

P

Saber W, Steinert P, Zhang M-J, Chen M, Pope A, Keating A, Wingard JR, Ballen K, Stiff P, Perales M-A, et al. A prospective cohort study comparing long-term outcomes with and without palifermin in patients receiving hematopoietic cell transplantation for hematologic malignancies. Transplant Cell Ther. 2021.

R

Algwaiz G, Aljurf M, Koh M, Horowitz MM, Ljungman P, Weisdorf D, Saber W, Kodera Y, Szer J, Jawdat D, et al. Real-world issues and potential solutions in HCT during the COVID-19 pandemic: Perspectives from the WBMT and the CIBMTR's Health Services and International Studies Committee. Biol Blood Marrow Transplant. 2020.